CS
Chongqing Sintaho Pharmaceutical Co., Ltd.
CDMO · Chongqing, China
GMP
Overview
Chongqing Sintaho Pharmaceutical was founded in 2016 and works in three areas: high-potency/cytotoxic APIs, peptides and XDC conjugate compounds, with API production and CDMO services. Its site says it passed FDA on-site inspections in 2024 and 2025. The FDA DMF list shows an active Type II DMF for semaglutide; its other DMFs include carfilzomib and oral GLP-1 orforglipron.
Capabilities
- Semaglutide API
- Cytotoxic and OEB5 high-potency APIs
- XDC conjugate compounds
- CDMO services
Quality signals
| GMP evidence | Yes |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |